Scarica l'app Stockscreener
3.22
9.52%
0.28
Dopo l'orario di chiusura:
3.24
0.02
+0.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio, Inc. (IBRX) Stock: An Under $5 Gem with Biggest Upside Potential - Insider Monkey
Why Did Immunitybio (IBRX) Go Down on Friday? - MSN
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Insider Monkey
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - MSN
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpTime to Buy? - MarketBeat
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.2%What's Next? - MarketBeat
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Target of Unusually Large Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Up 6.3%Here's Why - MarketBeat
ImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - Insider Monkey
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
ImmunityBio stock gains 15% amid regulatory updates (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances - MarketWatch
ImmunityBio shares surge following progress in FDA discussions By Investing.com - Investing.com Canada
ImmunityBio shares surge following progress in FDA discussions - Investing.com
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday - Benzinga
Anktiva targets expanded indication in US and global approvals in EU and UK - Urology Times
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom - BioSpace
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - BioSpace
How to spot and prevent hypothermia - AOL
Why ImmunityBio, Inc. (IBRX) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 5.2%Time to Sell? - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Sets New 12-Month LowHere's What Happened - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies By Investing.com - Investing.com South Africa
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio gains unique J-code for bladder cancer treatment - Investing.com
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective - The Bakersfield Californian
As ImmunityBio's Bladder Cancer Drug Gains Ground, Will The Stock Pick Up Steam? - RTTNews
ImmunityBio (NASDAQ:IBRX) Trading 7% HigherHere's What Happened - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat
ImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Barclays PLC - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Up 2.6%Time to Buy? - MarketBeat
IBRX Stock Hits 52-Week Low at $2.6 Amid Market Challenges - Investing.com
5 Companies That Celebrated First Approvals in 2024 - BioSpace
State Street Corp Purchases 790,408 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):